This section contains case studies, industry highlights, minireviews, and other articles for drug discovery professionals. Check out the resources page for posters, educational content, lists of drug approvals, and more.
AZD4205 is a JAK1-selective kinase inhibitor which is in clinical development for oncology rather than the inflammatory diseases most JAK1 inhibitors…
molecule
2 years ago ●
1 min read
QPX7728 is an ultrabroad-spectrum beta-lactamase inhibitor with activity against both serine and zinc metallo-beta-lactamases, in contrast to approved beta-lactamase inhibitors such…
molecule
2 years ago ●
1 min read
“Compound 9” is the first potent M3-selective positive allosteric modulator, with potential utility as a biological tool compound. It does have…
molecule
2 years ago ●
1 min read
“Compound (P)-14″ is a PI3K beta-isoform selective lipid kinase inhibitor. While the compound is potent and has excellent oral PK in…
molecule
2 years ago ●
1 min read
FT385 is a covalent inhibitor of the USP30 deubiquitinating enzyme with a cyanopyrrolidine warhead. Identifying selective active-site inhibitors of de-ubiquitinating enzymes…
molecule
2 years ago ●
1 min read
CC-92480 (Celgene/Bristol Myers Squibb (BMS) oral in vivo CRBN-based selective IKZF1/3 degrader)
molecule
2 years ago ●
1 min read
Load More
